A Study Of PF-04449913 In Select Hematologic Malignancies
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | March 2010 |
| End Date: | January 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway
on select hematologic malignancies.
Inclusion Criteria:
- Patients with select advanced hematologic malignancies who are refractory, resistant
or intolerant to prior therapies. They may be newly diagnosed and previously
untreated, but not eligible for standard treatment options, or for whom standard
therapies are not anticipated to result in a durable response.
- ECOG performance status 0 to 2
- Adequate organ function
Exclusion Criteria:
- Patients with active CNS disease
- Patient with active malignancy with the exception of basal cell carcinoma, non
melanoma skin cancer, carcinoma in situ cervical or skin cancer
- Active GVHD other than Grade 1 skin involvement
- Known malabsorption syndrome
- Patient has an active, life threatening or clinically significant uncontrolled
systemic infection
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials